Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

By sjmartinez • April 27, 2023

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Apr 26. doi: 10.1002/art.42510. Epub ahead of print. PMID: 37098795.

Tags: Publications, Rheumatology

Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS)

Blanco LR, Hays RD. Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS). J Retire. 2024 Fall;12(2):76-94. doi: 10.3905/jor.2024.1.164. Epub 2024 Oct[...]

Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease

Ko M, Barai R, Brent G. Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease. Cureus. 2024 Oct 15;16(10):e71551. doi: 10.7759/cureus.71551.[...]

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]